Phase 3 Clinical Trial Approved for Essential Hypertension Drug HCP1803-4: Pipeline Value Boost Expected
Hanmi Pharm received MFDS approval for its Phase 3 clinical trial plan for HCP1803-4, an essential hypertension treatment. This is a follow-up approval to the disclosure made in February 2026.
The Phase 3 trial is a multicenter, randomized, double-blind study involving 256 patients across 23 domestic hospitals, with the primary endpoint being the change in mean sitting systolic blood pressure at week 10.
The trial aims to demonstrate non-inferiority and safety of HCP1803-4 compared to the control drug (RLD2001-2), with an estimated duration of approximately 2 years from approval.
Investment caution: The statistical probability of a drug candidate receiving final approval is only about 10%. Commercialization plans may change or be abandoned based on results, so investors should consider all related risks.
[AI Comprehensive Analysis]This Phase 3 approval is a positive signal, advancing Hanmi Pharm's hypertension pipeline. However, significant uncertainties remain regarding clinical success and regulatory approval, warranting a medium- to long-term monitoring approach rather than short-term price surge expectations.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Approval of Phase 3 Clinical Trial Plan for HCP18034 Development by MFDS)